The TMD Prevention 2007 trial found that low-dose cytarabine treatment reduced mortality in TMD patients. However, this therapy did not prevent disease progression to ML-DS.
We have an open position for a skilled and dedicated postdoc in our new laboratory in Halle. Applications are welcome until the end of February. See the full post for more details.
The proceeds from this year's Charity Day were given to Pediatrics I of the Universitätsklinikum Halle. The funds will support research on leukemia in children with Down sydrome.
CRISPR-Cas9 genome editing was used to induce GATA1s in HSPCs of fetal, neonatal, and adult origin, leading to distinct ontogeny-specific disturbances in megakaryopoiesis and erythropoiesis.
The tumor suppressor miR-193b is downregulated in AML. Expression induces leukemic cell death through repression of MAPK signalling, making miR-193b a candidate for RNA-based therapy.
Introducing CRISPRater: a tool for more efficiently selecting effective sgRNAs in CRISPR-Cas9 applications. In addition, we provide a meta-analysis and individual evaluation of five current prediction algorithms.
Jan-Henning Klusmann will become full professor and department head of Pediatric Hematology/Oncology at the Universitätsklinikum Halle! He will begin there in January, and students will follow in March.
PD Dr. Jan-Henning Klusmann is a co-winner of the this year's Robert J. Arceci Award, a unique prize that offers resources and freedom to pioneers and innovators in childhood cancer research.
Our latest publication provides a non-coding RNA expression atlas across normal and malignant blood cells. We highlight the biological and clinical importance of ncRNAs, and the need for further study.
Two publications in one day: 1) Leveraging CRISPR-Cas9 to model translocation-driven leukemia yields new insight into the importance of environmental cues during disease induction.